Blog

Antibodies targeting metabotropic glutamate receptor 5 (mGluR5) were first identified in 2011 in 2 patients with Ophelia syndrome associated with Hodgkin lymphoma (HL) [1]. The clinical spectrum of anti-mGluR5 encephalitis is expanding from psychosis to cognitive impairment, seizures, and movement disorders as the number of reported patients increases [2, 3]. Of a total of 12 patients diagnosed with anti-mGluR5 encephalitis from publications, half developed seizures at different periods of disease progression, but none manifested as an isolated symptom of seizures [1–3].